In a landmark decision that could significantly impact the cardiac drug market in India, the Indian Patent Office (IPO) has revoked the patent for Novartis’ blockbuster heart failure medication, Vymada. The ruling, announced on September 16, 2025, cites lack of novelty and inventive step as the grounds for patent cancellation.
This move is poised to unleash a wave of generic drug competition, which could dramatically reduce treatment costs for thousands of cardiac patients across the country. The patent revocation is expected to increase access to affordable heart failure therapies and stimulate competition within India’s pharmaceutical sector.
The decision reflects India’s commitment to balancing patent protection with public health interests and follows a series of legal challenges by domestic drug manufacturers. Industry experts predict that multiple generic companies will soon enter the market, making Vymada therapy more accessible to a broader population.
